Alx Oncology Holdings (ALXO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alx Oncology Holdings stock (ALXO) is currently trading at $2.04. Alx Oncology Holdings PS ratio (Price-to-Sales) is 5906.24. Analyst consensus price target for ALXO is $4.60. WallStSmart rates ALXO as Sell.
- ALXO PE ratio analysis and historical PE chart
- ALXO PS ratio (Price-to-Sales) history and trend
- ALXO intrinsic value — DCF, Graham Number, EPV models
- ALXO stock price prediction 2025 2026 2027 2028 2029 2030
- ALXO fair value vs current price
- ALXO insider transactions and insider buying
- Is ALXO undervalued or overvalued?
- Alx Oncology Holdings financial analysis — revenue, earnings, cash flow
- ALXO Piotroski F-Score and Altman Z-Score
- ALXO analyst price target and Smart Rating
Alx Oncology Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Alx Oncology Holdings (ALXO) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Alx Oncology Holdings (ALXO) Key Strengths (0)
Supporting Valuation Data
Alx Oncology Holdings (ALXO) Areas to Watch (6)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 5906.2x annual revenue
Very expensive at 11.0x book value
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 40.29%
Supporting Valuation Data
Alx Oncology Holdings (ALXO) Detailed Analysis Report
Overall Assessment
This company scores 12/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (5906.24), Price/Book (11.02) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -145.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -145.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALXO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALXO's Price-to-Sales ratio of 5906.24x trades 159% above its historical average of 2280.83x (77th percentile), historically expensive. The current valuation is 38% below its historical high of 9567.84x set in Dec 2020, and 13013% above its historical low of 45.04x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~72.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Alx Oncology Holdings (ALXO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Alx Oncology Holdings operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -19M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Alx Oncology Holdings .
Bottom Line
Alx Oncology Holdings offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Alx Oncology Holdings (ALXO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.